{"id":"insulin-glulisine-qd","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin glulisine is a recombinant human insulin analog with rapid onset and short duration of action. It binds to the insulin receptor with similar affinity to human insulin but has faster absorption and earlier peak action, making it suitable for mealtime glucose control in diabetes. It promotes glucose uptake into peripheral tissues and suppresses hepatic glucose production.","oneSentence":"Insulin glulisine is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to facilitate glucose uptake and lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:23.326Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT01768559","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-01","conditions":"Type 2 Diabetes","enrollment":894},{"nctId":"NCT00135096","phase":"PHASE3","title":"Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-08","conditions":"Diabetes Mellitus, Type 2","enrollment":345},{"nctId":"NCT00135941","phase":"PHASE3","title":"Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-08","conditions":"Diabetes Mellitus","enrollment":582}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HMR1964","Device: Disposable self-injector prefilled pen (Apidra® Solostar®)"],"phase":"phase_3","status":"active","brandName":"Insulin glulisine QD","genericName":"Insulin glulisine QD","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin glulisine is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to facilitate glucose uptake and lower blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}